{"id":"W2617810686","doi":"10.1182/blood-2017-03-771220","title":"A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"Amyloidosis: Diagnosis, Treatment, Outcomes","field":"Biochemistry, Genetics and Molecular Biology","cited_by":122,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Ixazomib; AL amyloidosis; Medicine; Tolerability; Internal medicine; Adverse effect; Nausea; Gastroenterology; Refractory (planetary science); Bortezomib; Amyloidosis; Surgery; Multiple myeloma; Immunology; Carfilzomib; Immunoglobulin light chain; Antibody","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009501305,0.001238896,0.001519871,0.0002830291,0.0003034596,0.0004715767,0.000447114,0.000711529,0.001603668],"category_scores_gemma":[0.0004224251,0.0003956172,0.0005793129,0.0001941654,0.0004647668,0.000313085,0.0001727365,0.001804325,0.0004004044],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003752695,"about_ca_system_score_gemma":0.0007233729,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004979887,"about_ca_topic_score_gemma":0.001479573,"domain_scores_codex":[0.9997926,0.00009535966,0.000008466362,0.00003061759,0.00002285388,0.00005004058],"domain_scores_gemma":[0.9997717,0.00003804506,0.00004680323,0.00001875043,0.000015866,0.0001088387],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3361292,0.1065542,0.0121611,0.0013579,0.0009770668,0.001822144,0.0004539956,0.005282797,0.3122058,0.0004173694,0.006203046,0.2164353],"study_design_scores_gemma":[0.330526,0.6282675,0.01956905,0.00004554473,0.0003424799,0.001256342,0.00005525432,0.002713293,0.01280807,0.0002092067,0.004168795,0.00003850768],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9951478,0.001628244,0.0005331085,0.0002222026,0.00006046441,0.00124706,0.0003043221,0.00007089442,0.0007858973],"genre_scores_gemma":[0.9902334,0.002229988,0.002048074,0.0005719774,0.0001861515,0.001568974,0.001211836,0.00002599944,0.001923539],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001603668,"threshold_uncertainty_score":0.005364776,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02305316713436628,"score_gpt":0.3148848382474321,"score_spread":0.2918316711130658,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}